Your browser doesn't support javascript.
loading
Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics.
Colzani, E; Johansson, A L V; Liljegren, A; Foukakis, T; Clements, M; Adolfsson, J; Hall, P; Czene, K.
Afiliação
  • Colzani E; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
  • Johansson AL; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
  • Liljegren A; Department of Oncology, Radiumhemmet, Karolinska University Hospital, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
  • Foukakis T; Department of Oncology, Radiumhemmet, Karolinska University Hospital, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
  • Clements M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
  • Adolfsson J; Department of Clinical Science, Intervention and Technology, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
  • Hall P; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
  • Czene K; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
Br J Cancer ; 110(5): 1378-84, 2014 Mar 04.
Article em En | MEDLINE | ID: mdl-24434426
ABSTRACT

BACKGROUND:

Metastatic breast cancer is a severe condition without curative treatment. How relative and absolute risk of distant metastasis varies over time since diagnosis, as a function of treatment, age and tumour characteristics, has not been studied in detail.

METHODS:

A total of 9514 women under the age of 75 when diagnosed with breast cancer in Stockholm and Gotland regions during 1990-2006 were followed up for metastasis (mean follow-up=5.7 years). Time-dependent development of distant metastasis was analysed using flexible parametric survival models and presented as hazard ratio (HR) and cumulative risk.

RESULTS:

A total of 995 (10.4%) patients developed distant metastasis; the most common sites were skeleton (32.5%) and multiple sites (28.3%). Women younger than 50 years at diagnosis, with lymph node-positive, oestrogen receptor (ER)-negative, >20 mm tumours and treated only locally, had the highest risk of distant metastasis (0-5 years' cumulative risk =0.55; 95% confidence interval (CI) 0.47-0.64). Women older than 50 years at diagnosis, with ER-positive, lymph node-negative and ≤20-mm tumours, had the same and lowest cumulative risk of developing metastasis 0-5 and 5-10 years (cumulative risk=0.03; 95% CI 0.02-0.04). In the period of 5-10 years after diagnosis, women with ER-positive, lymph node-positive and >20-mm tumours were at highest risk of distant recurrence. Women with ER-negative tumours showed a decline in risk during this period.

CONCLUSION:

Our data show no support for discontinuation at 5 years of clinical follow-up in breast cancer patients and suggest further investigation on differential clinical follow-up for different subgroups of patients.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2014 Tipo de documento: Article